Bruce K. Rubin
Research Subjects
Research Interests
Bruce K. Rubin has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
Soichiro Kanoh
Department of Pediatrics, Virginia Commonwealth University School of Medicine, Richmond, VA
3 shared publicationsTsuyoshi Tanabe
Dept of Pediatrics, Virginia Commonwealth University School of Medicine, Richmond, VA, USA
3 shared publicationsH. Joel Schmidt
Department of Pediatrics, School of Medicine, Virginia Commonwealth University, Richmond, VA
2 shared publicationsAgathe Hoffer-Schaefer
Department of Pediatrics, Virginia Commonwealth University, Richmond, Virginia
1 shared publicationAnita Bhandari
Division of Pediatric Pulmonology, Connecticut Children's Medical Center, Hartford, Connecticut
1 shared publicationBruce C. Marshall
Cystic Fibrosis Foundation, Bethesda, Maryland, USA
1 shared publication
Latest Publications
- 1 November 2020
- Published by Elsevier in Paediatric Respiratory Reviews
- Vol. 36, 87-91
Electronic cigarettes and e-cigarette/vaping product use associated lung injury (EVALI)
- 1 November 2020
- Published by Elsevier in Paediatric Respiratory Reviews
- Vol. 36, 87-91
Electronic cigarettes and e-cigarette/vaping product use associated lung injury (EVALI)
- Top Cited Papers
- 1 September 2020
- Published by Elsevier in Paediatric Respiratory Reviews
- Vol. 35, 38-42
COVID-19 and telehealth, education, and research adaptations
- 1 September 2020
- Published by Elsevier in Paediatric Respiratory Reviews
- Vol. 35, 38-42
Top Cited PapersCOVID-19 and telehealth, education, and research adaptations
- 1 September 2016
- Published by Elsevier in Clinics in Chest Medicine
- Vol. 37 (3) , 405-408
Plastic Bronchitis
- 1 September 2016
- Published by Elsevier in Clinics in Chest Medicine
- Vol. 37 (3) , 405-408
Plastic Bronchitis
- Open Access
- 12 June 2015
- Published by SAGE Publications in Respiratory Care
- Vol. 60 (6) , 825-832
Aerosol Medications for Treatment of Mucus Clearance Disorders
Airway mucus hypersecretion and secretion retention can result from inflammation, irritation, stimulation, or mucus-producing tumors. Secretion clearance can be furthered hampered by ciliary dysfunction and by weakness or restrictive lung disease, leading to an ineffective cough. There are a number of different mucoactive medications that have been used to reduce hypersecretion, make secretions easier to transport, or increase the efficiency of cough or mucus clearance. In this paper, I review the pathophysiology of secretory hyper-responsiveness and mucus hypersecretion and discuss the different aerosol medications that can be used to augment secretion clearance.
- 12 June 2015
- Published by SAGE Publications in Respiratory Care
- Vol. 60 (6) , 825-832
Open AccessAerosol Medications for Treatment of Mucus Clearance Disorders
Airway mucus hypersecretion and secretion retention can result from inflammation, irritation, stimulation, or mucus-producing tumors. Secretion clearance can be furthered hampered by ciliary dysfunction and by weakness or restrictive lung disease, leading to an ineffective cough. There are a number of different mucoactive medications that have been used to reduce hypersecretion, make secretions easier to transport, or increase the efficiency of cough or mucus clearance. In this paper, I review the pathophysiology of secretory hyper-responsiveness and mucus hypersecretion and discuss the different aerosol medications that can be used to augment secretion clearance.
- 1 March 2015
- Published by Elsevier in Paediatric Respiratory Reviews
- Vol. 16 (2) , 83-87
Asthma myths, controversies, and dogma
- 1 March 2015
- Published by Elsevier in Paediatric Respiratory Reviews
- Vol. 16 (2) , 83-87
Asthma myths, controversies, and dogma
- 1 August 2014
- Published by Elsevier in Advanced Drug Delivery Reviews
- Vol. 75, 141-148
Emerging aerosol drug delivery strategies: From bench to clinic
- 1 August 2014
- Published by Elsevier in Advanced Drug Delivery Reviews
- Vol. 75, 141-148
Emerging aerosol drug delivery strategies: From bench to clinic
- 15 May 2014
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 44 (4) , 1002-1010
Club cell 10-kDa protein attenuates airway mucus hypersecretion and inflammation
Bacterial lipopolysaccharide (LPS) and interleukin (IL)-13 increase mucus secretion and inflammatory cytokine production in normal human bronchial epithelial (NHBE) cells. We evaluated the effect of club cell 10-kDa protein (CC10), an anti-inflammatory protein produced by epithelial cells, on mucus secretion, cell morphology and inflammatory cytokine production.NHBE cells were cultured at an air–liquid interface with CC10 or vehicle and exposed to LPS on day 14. Mucin MUC5AC, IL-8 and granulocyte-macrophage colony-stimulating factor were measured in cell supernatants. MUC5AC and IL-8 mRNA expression were measured by real-time PCR. Western blotting was used to evaluate nuclear factor (NF)-κB and extracellular signal-regulated kinase (ERK) activation. Cells were evaluated histologically. Additionally, NHBE cells were exposed to IL-13 and CC10 for 14 days, and secretion of the mucins MUC5AC and MUC5B was measured.MUC5AC secretion stimulated either by LPS or by IL-13 was attenuated by CC10 at 20 ng·mL−1(p−1also attenuated IL-8 secretion (p<0.05). MUC5AC and IL-8 mRNA expression were also decreased by CC10 (p<0.05). CC10 attenuated phosphorylation of NF-κB (p<0.05) and ERK1/2 (p<0.05).CC10 attenuates LPS-induced mucus secretion in airway cells, in part due to inhibition of NF-κB and ERK phosphorylation.
- 15 May 2014
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 44 (4) , 1002-1010
Club cell 10-kDa protein attenuates airway mucus hypersecretion and inflammation
Bacterial lipopolysaccharide (LPS) and interleukin (IL)-13 increase mucus secretion and inflammatory cytokine production in normal human bronchial epithelial (NHBE) cells. We evaluated the effect of club cell 10-kDa protein (CC10), an anti-inflammatory protein produced by epithelial cells, on mucus secretion, cell morphology and inflammatory cytokine production.NHBE cells were cultured at an air–liquid interface with CC10 or vehicle and exposed to LPS on day 14. Mucin MUC5AC, IL-8 and granulocyte-macrophage colony-stimulating factor were measured in cell supernatants. MUC5AC and IL-8 mRNA expression were measured by real-time PCR. Western blotting was used to evaluate nuclear factor (NF)-κB and extracellular signal-regulated kinase (ERK) activation. Cells were evaluated histologically. Additionally, NHBE cells were exposed to IL-13 and CC10 for 14 days, and secretion of the mucins MUC5AC and MUC5B was measured.MUC5AC secretion stimulated either by LPS or by IL-13 was attenuated by CC10 at 20 ng·mL−1(p−1also attenuated IL-8 secretion (p<0.05). MUC5AC and IL-8 mRNA expression were also decreased by CC10 (p<0.05). CC10 attenuated phosphorylation of NF-κB (p<0.05) and ERK1/2 (p<0.05).CC10 attenuates LPS-induced mucus secretion in airway cells, in part due to inhibition of NF-κB and ERK phosphorylation.
- Open Access
- 10 March 2014
- Published by Springer Nature in Translational Respiratory Medicine
- Vol. 2 (1) , 6
Secretion properties, clearance, and therapy in airway disease
Chronic airway diseases like cystic fibrosis, chronic bronchitis, asthma, diffuse panbronchiolitis, and bronchiectasis are all associated with chronic inflammation. The airway mucosa responds to infection and inflammation in part by surface mucous (goblet) cell and submucosal gland hyperplasia and hypertrophy with mucus hypersecretion. Products of inflammation including neutrophil derived DNA and filamentous actin, effete cells, bacteria, and cell debris all contribute to mucus purulence and, when this is expectorated it is called sputum. Mucus is usually cleared by ciliary movement, and sputum is cleared by cough. These airway diseases each are associated with the production of mucus and sputum with characteristic composition, polymer structure, and biophysical properties. These properties change with the progress of the disease making it possible to use sputum analysis to identify the potential cause and severity of airway diseases. This information has also been important for the development of effective mucoactive therapy to promote airway hygiene.
- 10 March 2014
- Published by Springer Nature in Translational Respiratory Medicine
- Vol. 2 (1) , 6
Open AccessSecretion properties, clearance, and therapy in airway disease
Chronic airway diseases like cystic fibrosis, chronic bronchitis, asthma, diffuse panbronchiolitis, and bronchiectasis are all associated with chronic inflammation. The airway mucosa responds to infection and inflammation in part by surface mucous (goblet) cell and submucosal gland hyperplasia and hypertrophy with mucus hypersecretion. Products of inflammation including neutrophil derived DNA and filamentous actin, effete cells, bacteria, and cell debris all contribute to mucus purulence and, when this is expectorated it is called sputum. Mucus is usually cleared by ciliary movement, and sputum is cleared by cough. These airway diseases each are associated with the production of mucus and sputum with characteristic composition, polymer structure, and biophysical properties. These properties change with the progress of the disease making it possible to use sputum analysis to identify the potential cause and severity of airway diseases. This information has also been important for the development of effective mucoactive therapy to promote airway hygiene.
- 1 March 2014
- Published by Elsevier in Paediatric Respiratory Reviews
- Vol. 15 (1) , 113-116
Cystic fibrosis: Myths. mistakes, and dogma
- 1 March 2014
- Published by Elsevier in Paediatric Respiratory Reviews
- Vol. 15 (1) , 113-116
Cystic fibrosis: Myths. mistakes, and dogma